Literature DB >> 18562596

Serum phosphate levels and risk of infection in incident dialysis patients.

Laura C Plantinga1, Nancy E Fink, Michal L Melamed, William A Briggs, Neil R Powe, Bernard G Jaar.   

Abstract

BACKGROUND AND OBJECTIVES: Hyperphosphatemia is highly prevalent in dialysis patients and may be associated with immune dysfunction. The association of serum phosphate level with infection remains largely unexamined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In an incident cohort of 1010 dialysis patients enrolled from 1995 to 1998 and treated in 80 US clinics, the association of phosphate level (low <3.5; normal 3.5 to 5.5; high >5.5 mg/dl) at baseline and during follow-up with the risk for incident inpatient and outpatient infection-related events was examined. Infectious events were identified from US Renal Data System data (mean follow-up 3.3 yr). Incidence rate ratios for all infections, sepsis, respiratory tract infections, and osteomyelitis were obtained using multivariable Poisson models, adjusting for potential confounders (age, race, gender, smoking, comorbidity, and laboratory values).
RESULTS: Infections of any type (n = 1398) were more frequent among patients with high phosphate levels at baseline, relative to normal; this association was not changed by adjustment for parathyroid hormone level. Similarly, high versus normal baseline phosphate was associated with increased risk for sepsis and osteomyelitis but not respiratory tract infections. Associations with calcium were generally NS, and results with calcium-phosphate product mirrored the phosphate results.
CONCLUSIONS: High phosphate levels may be associated with increased risk for infection, contributing further to the rationale for aggressive management of hyperphosphatemia in dialysis patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562596      PMCID: PMC2518791          DOI: 10.2215/CJN.00420108

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  32 in total

1.  Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial.

Authors:  D C Miskulin; N V Athienites; G Yan; A A Martin; D B Ornt; J W Kusek; K B Meyer; A S Levey
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

2.  Vitamin D in patients with chronic kidney disease: nothing new under the sun.

Authors:  Marcello Tonelli
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

3.  Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease.

Authors:  Dana C Miskulin; Klemens B Meyer; Nicolaos V Athienites; Alice A Martin; Norma Terrin; Jane V Marsh; Nancy E Fink; Josef Coresh; Neil R Powe; Mike J Klag; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 4.  Adjustments for center in multicenter studies: an overview.

Authors:  A R Localio; J A Berlin; T R Ten Have; S E Kimmel
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

5.  Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.

Authors:  Santhi K Ganesh; Austin G Stack; Nathan W Levin; Tempie Hulbert-Shearon; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

6.  Septicemia in diabetic hemodialysis patients: comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients.

Authors:  B G Jaar; J A Hermann; S L Furth; W Briggs; N R Powe
Journal:  Am J Kidney Dis       Date:  2000-02       Impact factor: 8.860

7.  Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.

Authors:  B C Astor; J A Eustace; N R Powe; M J Klag; J H Sadler; N E Fink; J Coresh
Journal:  Am J Kidney Dis       Date:  2001-09       Impact factor: 8.860

8.  The timing of specialist evaluation in chronic kidney disease and mortality.

Authors:  Kraig S Kinchen; John Sadler; Nancy Fink; Ronald Brookmeyer; Michael J Klag; Andrew S Levey; Neil R Powe
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

9.  Infectious complications of old nonfunctioning arteriovenous grafts in renal transplant recipients: a case series.

Authors:  George M Nassar; Juan Carlos Ayus
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

10.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.

Authors:  Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

View more
  11 in total

1.  Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study.

Authors:  Michel Chonchol; Tom Greene; Yingying Zhang; Andrew N Hoofnagle; Alfred K Cheung
Journal:  J Am Soc Nephrol       Date:  2015-05-13       Impact factor: 10.121

2.  Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization.

Authors:  Matthew Abramowitz; Paul Muntner; Maria Coco; William Southern; Irwin Lotwin; Thomas H Hostetter; Michal L Melamed
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 8.237

3.  Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Junichi Ishigami; Jonathan T Taliercio; Harold I Feldman; Anand Srivastava; Raymond R Townsend; Debbie L Cohen; Edward J Horwitz; Panduranga Rao; Jeanne Charleston; Jeffrey C Fink; Ana C Ricardo; James Sondheimer; Teresa K Chen; Myles Wolf; Tamara Isakova; Lawrence J Appel; Kunihiro Matsushita
Journal:  J Am Soc Nephrol       Date:  2020-06-23       Impact factor: 10.121

4.  Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders.

Authors:  Valeria Hasenmajer; Giulia Puliani; Marianna Minnetti; Emilia Sbardella; Claudio M Mastroianni; Gabriella D'Ettorre; Andrea M Isidori; Daniele Gianfrilli
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Inpatient hemodialysis initiation: reasons, risk factors and outcomes.

Authors:  Deidra C Crews; Bernard G Jaar; Laura C Plantinga; Hania S Kassem; Nancy E Fink; Neil R Powe
Journal:  Nephron Clin Pract       Date:  2009-10-09

6.  Peripheral vascular disease-related procedures in dialysis patients: predictors and prognosis.

Authors:  Laura C Plantinga; Nancy E Fink; Josef Coresh; Stephen M Sozio; Rulan S Parekh; Michal L Melamed; Neil R Powe; Bernard G Jaar
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-13       Impact factor: 8.237

7.  Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study.

Authors:  Junichi Ishigami; Bernard G Jaar; Casey M Rebholz; Morgan E Grams; Erin D Michos; Myles Wolf; Csaba P Kovesdy; Shinichi Uchida; Josef Coresh; Pamela L Lutsey; Kunihiro Matsushita
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

8.  Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

Authors:  Angel L M de Francisco; Michael Leidig; Adrian C Covic; Markus Ketteler; Ewa Benedyk-Lorens; Gabriel M Mircescu; Caecilia Scholz; Pedro Ponce; Jutta Passlick-Deetjen
Journal:  Nephrol Dial Transplant       Date:  2010-06-07       Impact factor: 5.992

9.  Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS.

Authors:  Marcelo Barreto Lopes; Angelo Karaboyas; Brian Bieber; Ronald L Pisoni; Sebastian Walpen; Masafumi Fukagawa; Anders Christensson; Pieter Evenepoel; Marisa Pegoraro; Bruce M Robinson; Roberto Pecoits-Filho
Journal:  Nephrol Dial Transplant       Date:  2020-10-01       Impact factor: 5.992

10.  A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

Authors:  Adrian Covic; Jutta Passlick-Deetjen; Miroslaw Kroczak; Beatrix Büschges-Seraphin; Adrian Ghenu; Pedro Ponce; Barbara Marzell; Angel L M de Francisco
Journal:  Nephrol Dial Transplant       Date:  2013-06-19       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.